Biosense Webster
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Biosense Webster sits in the top decile of US sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count).
Biosense Webster: 18 sponsored US clinical trials, 4 recruiting.
Biosense Webster sponsors 18 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 12 completed. 8 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Atrial Fibrillation, with 3 trials.
Top-decile sponsor footprint
Biosense Webster ranks in the top decile of sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
12 of 13 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (92.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
18 total, page 1 of 1
A Study of VARIPULSE Catheter in Participants With Persistent Atrial Fibrillation Undergoing Pulmonary Vein and Superior Vena Cava Isolation
NCT07527299
A Study of VARIPULSE Pulsed Field Ablation (PFA) Catheter and FARAWAVE PFA Catheter in the Treatment of Participants With Persistent Atrial Fibrillation
NCT07523750
A Study Assessing Long-Term Safety and Effectiveness in Treatment Management of Atrial Fibrillation With VARIPULSE Catheter System
NCT07227532
A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF)
NCT06455098
An Early Feasibility Study Evaluating the Safety and Efficacy of the Laminar Left Atrial Appendage Closure System in Subjects With Non-Valvular Atrial Fibrillation
NCT05565599
A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAF
NCT06144632
Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation With the BWI IRE Ablation System
NCT05293639
Evaluation of QDOT MICRO™ Catheter for Pulmonary Vein Isolation in Subjects With Paroxysmal Atrial Fibrillation
NCT03775512
Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation
NCT03683030
Evaluation of VISITAG SURPOINT™ Module With External Processing Unit (EPU)
NCT03624881
CARTO® 3 System and Real Time Intracardiac Ultrasound
NCT01716663
THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS
NCT01639495
Early Ablation Therapy for the Treatment of Ischemic Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillators
NCT01557842
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study
NCT01585961
Selective Complex Fractionated Atrial Electrograms (CFAE) Targeting for Atrial Fibrillation
NCT00926783
Catheter Evaluation for Endocardial Ablation in Patients With Typical Atrial Flutter
NCT00318565
NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation
NCT00116428
A Comparison of Antiarrhythmic Drug Therapy and Radio Frequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
NCT00540787
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 3 |
| Phase 4 | 5 |
Therapeutic Areas
Where Biosense Webster enrollment is open (later-stage tilt)
4 recruiting of 18 indexed (22% open); 12 completed (67%).
Phase mix: 8 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Atrial Fibrillation (3 trials), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Biosense Webster: open-pipeline peers nationwide
Peers matched on 18 registered trials and 22% open enrollment, not the therapeutic-area sidebar.
Biosense Webster sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 18 trials (± recruiting share)
- ADC Therapeutics S.A. · 18 trials · 11% recruiting
- Akros Pharma · 18 trials · 0% recruiting
- AO Clinical Investigation and Publishing Documentation · 18 trials · 0% recruiting
- AO Innovation Translation Center · 18 trials · 33% recruiting
Sponsors near 22% open enrollment (± trial volume)
- ALX Oncology · 22% recruiting · 9 trials
- Englewood Hospital and Medical Center · 22% recruiting · 18 trials
- Ensysce Biosciences · 22% recruiting · 9 trials
- Harvard University Faculty of Medicine · 22% recruiting · 9 trials
Related
What to do with this Biosense Webster page
18 registered trials is a research-attention snapshot, not an endorsement of Biosense Webster or any single study.
- 4 of Biosense Webster's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Atrial Fibrillation is the condition Biosense Webster studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Atrial Fibrillation trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Biosense Webster pipeline card: 18 registered trials from official public datasets.Report a data error.